The Application of Nanobody in CAR-T Therapy
Open Access
- 8 February 2021
- journal article
- review article
- Published by MDPI AG in Biomolecules
- Vol. 11 (2), 238
- https://doi.org/10.3390/biom11020238
Abstract
Chimeric antigen receptor (CAR) T therapy represents a form of immune cellular therapy with clinical efficacy and a specific target. A typical chimeric antigen receptor (CAR) construct consists of an antigen binding domain, a transmembrane domain, and a cytoplasmic domain. Nanobodies have been widely applied as the antigen binding domain of CAR-T due to their small size, optimal stability, high affinity, and manufacturing feasibility. The nanobody-based CAR structure has shown a proven function in more than ten different tumor-specific targets. After being transduced in Jurkat cells, natural killer cells, or primary T cells, the resulting nanobody-based CAR-T or CAR-NK cells demonstrate anti-tumor effects both in vitro and in vivo. Interestingly, anti-BCMA CAR-T modulated by a single nanobody or bi-valent nanobody displays comparable clinical effects with that of single-chain variable fragment (scFv)-modulated CAR-T. The application of nanobodies in CAR-T therapy has been well demonstrated from bench to bedside and displays great potential in forming advanced CAR-T for more challenging tasks.This publication has 118 references indexed in Scilit:
- Nanobodies: Natural Single-Domain AntibodiesAnnual Review of Biochemistry, 2013
- Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in miceJCI Insight, 2010
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In VivoMolecular Therapy, 2009
- Anti-MUC1 Nanobody Can Redirect T-Body Cytotoxic Effector FunctionHybridoma, 2009
- Construction of a Human Antibody Domain (VH) LibraryMethods in molecular biology (Clifton, N.J.), 2008
- Optimized production and concentration of lentiviral vectors containing large insertsThe Journal of Gene Medicine, 2007
- CD28 Costimulation Provided through a CD19-Specific Chimeric Antigen Receptor EnhancesIn vivoPersistence and Antitumor Efficacy of Adoptively Transferred T CellsCancer Research, 2006
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Clinical Trials: IL-12 Deaths: Explanation and a PuzzleScience, 1995
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaThe New England Journal of Medicine, 1988